Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
Article
Google Scholar
Raghu G, Chen S-Y, Yeh W-S, Maroni B, Li Q, Lee Y-C, Collard HR. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir Med. 2014;2:566–72.
Article
Google Scholar
King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92.
Article
Google Scholar
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.
Article
Google Scholar
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T, Japan tPCSGi. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–9.
Article
CAS
Google Scholar
Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, Klotsche J, Andreas S, Claussen M, Grohé C. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020;56(2):1902279.
Article
Google Scholar
Wada H, Ikeda A, Maruyama K, Yamagishi K, Barnes PJ, Tanigawa T, Tamakoshi A, Iso H. Low BMI and weight loss aggravate COPD mortality in men, findings from a large prospective cohort: the JACC study. Sci Rep. 2021;11:1–9.
Article
Google Scholar
McDonald M-LN, Wouters EF, Rutten E, Casaburi R, Rennard SI, Lomas DA, Bamman M, Celli B, Agusti A, Tal-Singer R. It’s more than low BMI: prevalence of cachexia and associated mortality in COPD. Respir Res. 2019;20:1–9.
Article
Google Scholar
Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Prevalence and burden of comorbidities in chronic obstructive pulmonary disease. Respir Investig. 2016;54:387–96.
Article
Google Scholar
Wada H, Ikeda A, Maruyama K, Yamagishi K, Barnes PJ, Tanigawa T, Tamakoshi A, Iso H. Low BMI and weight loss aggravate COPD mortality in men, findings from a large prospective cohort: the JACC study. Sci Rep. 2021;11:1531.
Article
CAS
Google Scholar
McDonald MN, Wouters EFM, Rutten E, Casaburi R, Rennard SI, Lomas DA, Bamman M, Celli B, Agusti A, Tal-Singer R, Hersh CP, Dransfield M, Silverman EK. It’s more than low BMI: prevalence of cachexia and associated mortality in COPD. Respir Res. 2019;20:100.
Article
Google Scholar
Watte G, Nunes CHA, Sidney-Filho LA, Zanon M, Altmayer SPL, Pacini GS, Barros M, Moreira ALS, Alves RJV, Zelmanowicz AM, Matata BM, Moreira JDS. Proportional weight loss in six months as a risk factor for mortality in stage IV non-small cell lung cancer. J Bras Pneumol. 2018;44:505–9.
Article
Google Scholar
Chen YM, Lai CH, Lin CY, Tsai YH, Chang YC, Chen HC, Tseng CC, Chang HC, Huang KT, Chen YC, Fang WF, Wang CC, Chao TY, Lin MC. Body mass index, weight loss, and mortality risk in advanced-stage non-small cell lung cancer patients: a focus on EGFR mutation. Nutrients. 2021;13:3761.
Article
CAS
Google Scholar
Mytelka DS, Li L, Benoit K. Post-diagnosis weight loss as a prognostic factor in non-small cell lung cancer. J Cachexia Sarcopenia Muscle. 2018;9:86–92.
Article
Google Scholar
Nakatsuka Y, Handa T, Kokosi M, Tanizawa K, Puglisi S, Jacob J, Sokai A, Ikezoe K, Kanatani KT, Kubo T. The clinical significance of body weight loss in idiopathic pulmonary fibrosis patients. Respir Int Rev Thorac Dis. 2018;96:338–47.
Google Scholar
Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest. 2007;131:1448–53.
Article
Google Scholar
Schols AM, Ferreira IM, Franssen FM, Gosker HR, Janssens W, Muscaritoli M, Pison C, Rutten-vanMölken M, Slinde F, Steiner MC. Nutritional assessment and therapy in COPD: a European Respiratory Society statement. Eur Respiratory Soc. 2014;44:1504.
Article
Google Scholar
Pugashetti J, Graham J, Boctor N, Mendez C, Foster E, Juarez M, Harper R, Morrissey B, Kadoch M, Oldham JM. Weight loss as a predictor of mortality in patients with interstitial lung disease. Eur Respir J. 2018;52:1801289.
Article
Google Scholar
Comes A, Wong AW, Fisher JH, Morisset J, Johannson KA, Farrand E, Fell CD, Kolb M, Manganas H, Cox G, Gershon AS, Halayko AJ, Hambly N, Khalil N, Sadatsafavi M, Shapera S, To T, Wilcox PG, Collard HR, Ryerson CJ. Association of BMI and change in weight with mortality in patients with fibrotic interstitial lung disease. Chest. 2022;161:1320–9.
Article
Google Scholar
Awano N, Jo T, Yasunaga H, Inomata M, Kuse N, Tone M, Morita K, Matsui H, Fushimi K, Nagase T, Izumo T. Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis. ERJ Open Res. 2021;7:00037–2021.
Article
Google Scholar
Gao J, Kalafatis D, Carlson L, Pesonen IHA, Li CX, Wheelock Å, Magnusson JM, Sköld CM. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respir Res. 2021;22:40.
Article
CAS
Google Scholar
Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY Trial. Am J Respir Crit Care Med. 2018;197:356–63.
Article
CAS
Google Scholar
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718–27.
Article
CAS
Google Scholar
Ikeda S, Sekine A, Baba T, Katano T, Tabata E, Shintani R, Sadoyama S, Yamakawa H, Oda T, Okuda R. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2019;19:1–11.
Article
Google Scholar
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–68.
Article
Google Scholar
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646–64.
Article
Google Scholar
American Thoracic S, European Respiratory S. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002; 165:277–304.
Dolivo DM, Larson SA, Dominko T. Tryptophan metabolites kynurenine and serotonin regulate fibroblast activation and fibrosis. Cell Mol Life Sci. 2018;75:3663–81.
Article
CAS
Google Scholar
Kennedy JI, Chandler DB, Fulmer JD, Wert MB, Grizzle WE. Dietary fish oil inhibits bleomycin-induced pulmonary fibrosis in the rat. Exp Lung Res. 1989;15:315–29.
Article
CAS
Google Scholar